The Deubiquitinating Enzyme Inhibitor PR-619 Enhances the Cytotoxicity of Cisplatin via the Suppression of Anti-Apoptotic Bcl-2 Protein: In Vitro and In Vivo StudyKuan-Lin Kuo, Kuo‐How Huang, Shing‐Hwa Liu et al.|Cells|2019Cited by 28
PR-619, a General Inhibitor of Deubiquitylating Enzymes, Diminishes Cisplatin Resistance in Urothelial Carcinoma Cells through the Suppression of c-Myc: An In Vitro and In Vivo StudyFu-Shun Hsu, Kuo‐How Huang, Ruei-Je Chang et al.|International Journal of Molecular Sciences|2021Cited by 27
Neddylation inhibitor, MLN4924 suppresses angiogenesis in huvecs and solid cancers: <i>in vitro</i> and <i>in vivo</i> study.Chung‐Sheng Shi, Kuo‐How Huang, Kuan-Lin Kuo et al.|PubMed|2020Cited by 26
Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK PathwayFu-Shun Hsu, Kuo‐How Huang, June‐Tai Wu et al.|International Journal of Molecular Sciences|2019Cited by 25
Trifluoperazine, an Antipsychotic Drug, Effectively Reduces Drug Resistance in Cisplatin-Resistant Urothelial Carcinoma Cells via Suppressing Bcl-xL: An In Vitro and In Vivo StudyKuan-Lin Kuo, Kuo‐How Huang, Shing‐Hwa Liu et al.|International Journal of Molecular Sciences|2019Cited by 25